智通财经网·2025-11-11 04:01Core Viewpoint - China National Pharmaceutical Group (国药控股) shares have risen over 3%, reaching a new high of 20.86 HKD this year, driven by positive market sentiment and analyst recommendations [1] Group 1: Stock Performance - As of the report, the stock price increased by 3.49%, trading at 20.78 HKD with a transaction volume of 111.2 million HKD [1] - The stock has been positively influenced by a report from Morgan Stanley, which predicts a 70% to 80% chance of price increase within the next 30 days, with a target price set at 22.5 HKD [1] Group 2: Company Performance - Morgan Stanley noted that despite weak domestic demand and ongoing technology licensing activities in China, the pharmaceutical distributor is expected to gain attention by 2025 [1] - The company is currently viewed as a good entry point based on a projected price-to-earnings ratio of 6.5 times for 2026 [1] Group 3: Subsidiary Performance - Two subsidiaries of China National Pharmaceutical Group reported third-quarter results showing positive trends, contributing to the overall group performance [1] - China National Pharmaceutical Co., as a distributor in Beijing and a major supplier of anesthetics, reported a year-on-year revenue and profit increase of 4% and 13%, respectively [1] - China National Pharmaceutical's subsidiary, which manages the southern distribution network and the Guoda Pharmacy chain, experienced a year-on-year revenue and net profit decline of 2% and 10%, but indicated that the distribution business is stabilizing and returning to growth [1]